Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of TAK-881 in primary immunodeficiency diseases
NL-OMON59053Phase 3Completed
- Sponsor
- Takeda
- Start
- Apr 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of TAK-881 in Immunogenetic disorder, sponsored by Takeda. Started Apr 2025; status: completed.
02
Drugs
TAK-881
03
Conditions
Immunogenetic disorder
Beyond the preview
Go deeper on NL-OMON59053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59053.